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AN INSTITUTIONAL PERSPECTIVE ON THE EFFICACY OF DONOR LEUKO-
CYTE INFUSIONS FOR PATIENTS WITH POST-TRANSPLANT RELAPSE
Myers, L.1, Burmeister, J.1, Mater, E.1, Murray, S.1, Curtin, P.T.2,
Gajewski, J.L.1, Hayes-Lattin, B.1, Kovacsovics, T.1, Leis, J.F.3,
Meyers, G.1, Slater, S.1, Maziarz, R.T.1 1Oregon Health and Science
University, Portland, OR; 2University of California San Diego, San
Diego, CA; 3Mayo Clinic Hospital, Scottsdale, AZ
Patients with post-allogeneic HSCTdisease relapse can be treated
with salvage chemotherapy but are also candidates for immune sup-
pression withdrawal and/or donor lymphocyte infusion (DLI).
A total of 237 adult patients experienced relapse of disease post-al-
logeneic transplant at our institution between 1995 and 2010. A ret-
rospective institutional analysis was performed on the 52 patients
who received DLI in that timeframe. The DLI product infusion
doses ranged from 0.07 to 4.0 x 108 CD3+ cells.
CML patients had the most favorable DLI response rates with
78% (n 5 7) in remission at 3 years. Patients with relapsed AML/
MDS and lymphoid malignancies fared worse with 36% and 21%
OS at 3 years respectively. OS was superior in patients in CR prior
to DLI (45%) compared to those with active disease (5%) and for pa-
tients under the age of 50 (32% vs 21%). Three year OS was ob-
served of 5% for patients who relapsed prior to day +100, 29% for
relapse between day +100 and 1 year, and 59% for relapse after 1
year. Patients who developed GvHD prior to relapse had a 3 year
OS of 35% vs 9% in patients without GvHD. Patients with post-
DLI GvHD had a 39%OS vs 11% for patients without GvHD after
DLI. No difference in post-DLI survival was noted with regards to
pre-transplant disease status, cell dose or transplant conditioning.
CML patients respond well to DLI however in the TKI era, trans-
plants for these patients are reserved for patients with TKI-resistant
disease. In other patients, immune suppression withdrawal and DLI
have limited efficacy for those who do not achieveCR post-relapse or
who relapse within 3 months of transplant. These patients are in
need of alternative treatment strategies.394
PRECONDITIONING WITH RAPAMYCIN AND CTLA4-Ig IN DOGS GIVEN
DONOR ANTIGEN AND 1Gy TOTAL BODY IRRADIATION (TBI) BEFORE
DOG-LEUKOCYTE-ANTIGEN (DLA)-IDENTICAL MARROW TRANSPLAN-
TATION FAILED TO ASSURE SUSTAINED ENGRAFTMENT
Wang, Z.1,2, Sorror, M.L.1,2, McCune, J.S.1,3, Butts, T.1,
Graves, S.G.1,2, Storb, R.1,2 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Washington, Seattle, WA; 3University of
Washington, Seattle, WA
Stable engraftment of allogeneic, DLA-identical marrow can be
achieved by conditioning dogs with a nonmyeloablative dose of 2
Gy TBI followed by a brief course of postgrafting immunosuppres-
sion with cyclosporine (CSP) and mycophenolate mofetil (MMF).
However, when TBI dose was reduced to 1 Gy, CSP/MMF failed to
control host-versus-graft (HVG) reactions, and grafts were uniformly
rejected. CTLA4-Ig blocks T-cell costimulation through the
B7:CD28 signaling pathway and induces T cell anergy. We used
CTLA4-Ig concurrently with infusion of donor peripheral blood
mononuclear cells (PMBC) to blunt activated recipient T cells before
transplantation (Storb et al., Blood 94, p2523-2529, 1999). The regi-
men was effective in establishing stable mixed chimerism in67% of
the animals. Rapamycin mediates immunosuppression by inhibiting
both cytokine driven pathways and costimulatory signaling, and has
been reported to act in synergy with CTLA4-Ig for tolerance induc-
tion in solid organ transplantation. In the current study we asked
weather adding rapamycin to CTLA4-Ig before transplantation
would improveour earlier results and further aid in sustaining engraft-
ment. Accordingly, six recipient dogs were given CTLA4-Ig on days
-7 to -1 and rapamycin on days -6 to -2, with concurrent intravenous
administration of 10^6 (n5 2) or 10 x 10^6 (n5 4) PBMC from their
respective DLA-identical donors from days -7 to -1 before 1Gy TBI,
and CSP/MMF after marrow transplantation. The regimen was well
tolerated and all 6 dogs showed initial allogeneic engraftment. Only
one dog showed persistent mixed chimerism for more than 34 weeks
while 5 dogs rejected their allografts between 8 to 12 weeks followed
by autologous marrow recovery, a timing that was comparable to thatin control dogs. These findings illustrate the difficulty to achieve uni-
form sustained engraftment in DLA-identical dogs using pharmaco-
logical immunosuppression in combination with 1 Gy TBI.395
EVALUATION OF HCT-CI COMORBIDITY SCORES AND ALLOGENEIC
TRANSPLANT OUTCOME OF YOUNG ADULTS AFTER MYELOABLATIVE
CONDITIONING WITH FLUDARABINE AND BUSULFAN +/- TBI MALIG-
NANCIES
Slaby, J.1, Williamson, T.3, Chaudhry, A.M.1, Larratt, L.2,
Turner, R.A.2, Bahlis, N.J.1, Brown, C.B.1, Daly, A.1, Duggan, P.1,
Geddes, M.1, Quinlan, D.1, Savoie, M.L.1, Shafey, M.1, Storek, J.1,
Yue, P.1, Zacarias, N.1, Stewart, D.A.1, Russell, J.A.1, Russell, J.1 1Foot-
hills Medical Center and Tom Baker Cance Centre, Calgary, AB, Canada;
2Cross Cancer Institute, Edmonton, AB, Canada; 3Queen’s University,
Kingston, ON, Canada
We have previously reported an association between HCT-CI
scores 1 and more and increased TRM in allogeneic patients older
than 50 years. Now, we have analyzed HST-CI in 411 consecutive
younger patients with hematologic malignancy transplanted be-
tween 1999 and 2008.
Two hundred and thirty four patients had low-risk disease (ALCR
1 or 2, CMLCP), all others were considered high-risk. The myeloa-
blative regimen included fludarabine 250mg/m2 and intravenous bu-
sulfan 12.8mg/kg, 203 patients (49.4%) received additional TBI
(400cGy). CsA, MTX and Thymoglobulin (4.5mg/kg) were given
for GVHD prophylaxis. Donors were matched siblings in 208 cases
(50.6%); bone marrow, peripheral and umbilical blood were used in
73 (17.8%), 327 (79.5%) and 11 (2.7%) patients, respectively. Me-
dian age was 40 years (range 16-50) and median follow-up was 38
months (1-148 mo).
HCT-CI scoreswere0 in287 (70%), 1 in68 (16.5%),2 in27 (6.5%),
3 in22 (5.3%) and4 in7 (1.7%)patients.TRMofpatientswith score 0,
1, 2, or 3+was 13%, 12%, 33%and10%at1 year (p50.022) and14%,
15%, 33% and 14% at 3 years (p5 0.074), respectively.
Multivariate analysis only demonstrated an association of TRM
with HCT-CI score 2 (SHR 5 2.75; 95%CI: 1.27-5.98; p 5 0.01).
Three other factors were also significant: CMV status (SHR 5
2.02; 95%CI 1.1-3.71; p 5 0.024), alternative donor (SHR 5 1.95;
95%CI 1.17-3.25; p 5 0.010) and age (SHR 5 1.03 per year; 95%
CI 1.0-1.07; p 5 0.042).
Conclusions:
1. In contrast to older patients, the TRM of the combined group of
patients given a score of 1 and more was no different from those
with a score of 0.
2. Patients with score of 2 had significantly higher TRM.
3. Scores of 3 and 4 mostly represented previous malignancies and
pulmonary disease and did not seem to influence TRM in these
patients.
4. Increasing HCT-CI scores did not accurately reflect increasing
TRM in young patients treated with this regimen.396
PLATELET REFRACTORINESS IS ASSOCIATED WITH DELAYED PLATELET
ENGRAFTMENT AND INCREASED GRAFT VERSUS HOST DISEASE FOL-
LOWING PERIPHERAL BLOOD OR BONE MARROW DERIVED STEM
CELL TRANSPLANTATION
Gandhi, M.J., Schneider, B.A., Jenkins, S., Hogan, W.J., Litzow, M.R.,
Gastineau, D.A., Stubbs, J.R., Patnaik,M.S.Mayo Clinic, Rochester,MN
Background: Platelets (PLT) play a role in innate and adaptive im-
munity and possess pro-inflammatory, as well as pro-thrombotic
properties. PLT transfusion is associated with transfusion immuno-
modulation, resulting in alteration of the recipients’ immune func-
tion. Multiple PLT transfusions may result in alloimmunization
leading to refractoriness and greater transfusion requirements.
PLT refractoriness is relatively more common in patients undergo-
ing stem cell transplantation (SCT) for hematologic malignancies.
We analyzed the clinical outcomes in SCT patients with PLT
refractoriness.
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(n 5 64) from January 1, 2009 to December 31, 2009 at our institu-
tion undergoing allogeneic SCT for hematologic malignancies. PLT
refractoriness was defined as a clinical requirement for platelet cross-
matching. Clinical outcomes studied included day 100 and one year
survival, platelet and neutrophil engraftment and acute GVHD inci-
dence. Risks of death and GVHD were compared between groups
with logrank tests and were estimated with the Kaplan-Meier
method. Number of days to platelet or neutrophil engraftment was
compared with the Wilcoxon rank-sum test.
Results: Allogeneic SCT was performed in 64 patients including
three pediatric patients. 10/64 (16%) patients demonstrated PLT re-
fractoriness. Patients with PLT refractoriness had higher risk of
acute GVHD (Grade I-IV) as compared to non refractory patients
(p 5 0.046). Excluding patients without platelet engraftment due
to early death, patients with pretransplant PLT refractoriness (n 5
9) had delayed PLT engraftment, median (IQR) 5 27 days (19.5-
64.50) compared to non-refractory patients (n 5 52), median
(IQR) 5 19 days (16-23) (p 5 0.01). However, there was no signifi-
cant differences in terms of overall survival, GVHD grade II-IV or
time to neutrophil engraftment
Conclusions: PLT refractoriness may be associated with increased
incidence of acute GVHD and delayed platelet engraftment result-
ing in longer platelet transfusion support. A larger study is planned
to confirm these findings.397
RADIOTHERAPEUTIC TECHNIQUES IN ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANT (HCT)
Barker, C.A.1, Hong, S.2, Klein, J.P.2, Shaw, P.3, Bredeson, C.4,
Angelina, A.5, Rowlings, P.6, Cahn, J.-Y.7, Kharfan-Dabaja, M.8,
Aljurf, M.9, Szer, J.10, Wood, W.A.11, Ahmed, I.12, Gomez
Almaguer, D.13, Atsuta, Y.14, Sanz, M.15, Hale, G.16, Litzow, M.17,
Pasquini, M.C.2 On Behalf of the CIBMTR International Studies Com-
mittee 1Memorial Sloan-Kettering Cancer Center; 2CIBMTR, Medical
College of Wisconsin; 3The Children’s Hospital at Westmead; 4Ottawa
Hospital Blood and Marrow Transplant Program; 5No Institution; 6Cal-
vary Mater New Castle; 7Hospital A. Michallon, CHU de Grenoble;
8American University of Beirut; 9King Faisal Specialist Hospital & Re-
search Center; 10Royal Melbourne Hospital; 11University of North Caro-
lina Hospitals; 12University of New Mexico; 13Hospital Universidad
Autonoma de Nuevo Leon; 14Nagoya University Graduate School of Med-
icine; 15Hospital Universitario La Fe; 16All Children’s Hospital; 17Mayo
Clinic Rochester
Radiotherapy (RT) is used as an antineoplastic and immunomod-
ulatory therapy prior to allogeneic HCT. The practice of incorpo-
rating RT as part of HCT varies widely across centers worldwide.
The present study explores the use of RT in 14,920 allogeneic
HCT recipients (total body irradiation [TBI], N5 14,696, and total
lymphoid irradiation [TLI], N5 402) reported to the Center for In-
ternational Blood and Marrow Transplant Research between 1995
and 2010. TBI was performed in 335 reporting centers in 42 coun-
tries. The median age of TBI recipients was 33 years and the median
age increased from 31 to 39 years during the period (p\0.0001). TBI
was most commonly use in HCT for acute lymphocytic leukemia
(87%) and in patients with prior central nervous system (CNS) leu-
kemia involvement (76%, p\0.001). Shielding was used in 52% of
patients, commonly for lungs (72%) and eyes (14%). The median
dose of TBI was 12 Gy, with most patients receiving 2 fractions
per day (60%, p\0.0001), for total of 6 doses (34%, p\0.0001).
Myeloablative TBI doses (.8 Gy) decreased from 94% to 63% dur-
ing the period (p\0.001). Conversely, reduced intensity and non-
myeloablative (RI/NMA) TBI doses increased from\1% to 36%
(p\0.001). TBI was most frequently combined with cyclophospha-
mide (97%) in myeloablative regimens and fludarabine (68%) in
RI/NMA regimens. 11% of patients who received TBI also received
RTwithin 14 days of starting conditioning; treatmentwas directed at
the CNS (35%) and gonads (41%). TLI was performed in 70 centers
in 22 countries. The median age for TLI recipients was 37 years and
the median age increased from 29 to 56 years during the period. The
most common indications for TLI was severe aplastic anemia (SAA)
(23%) and acute myeloid leukemia (AML) (19%). TLI for SAA de-
creased from 47% to 0% while TLI for AML increased from 11%to 40% during the period. The median TLI dose was 6 Gy, with
most patients receiving 6 fractions (41%). 4% of patients who re-
ceived TLI also received RTwithin 14 days of starting conditioning;
treatment was most often directed at the spleen (47%). RT practices
in HCT changed during the past 16 years. There was a significant
decrease use of myeloablative TBI and increase in RI/NMA TBI.
Similarly, TLI practices changed towards a RI/NMA approach, be-
ing applied more frequently in older patients for treatment of malig-
nant diseases.
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PREDICTIVE FACTORS FOR ADVERSE OUTCOMES AFTER USE OF DONOR
CELL INFUSION (DCI) IN PATIENTS WITH RELAPSED HEMATOLOGICAL
MALIGNANCIES TREATED WITH ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (AlloHCT)
Bejanyan, N.1, Bolwell, B.1, Rybicki, L.2, Abounader, D.1, Duong, H.1,
Dean, R.1, Sobecks, R.1, Andresen, S.1, Pohlman, B.1, Copelan, E.1,
Kalaycio, M.1 1Taussig Cancer Institute, Cleveland Clinic, Cleveland,
OH; 2Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
DCI is administered after AlloHCT to enhance the graft-versus
leukemia effect and thereby induce remission in patients (pts) with
relapsed hematological malignancies. The purpose of this retrospec-
tive study was to identify risk factors for post-DCI progression and
mortality.
We identified 47 pts with hematological malignancies who re-
ceived DCI from 02/1996 to 07/2011 for disease relapse. We ana-
lyzed variables such as pts baseline demographics, malignancy
type, donor relationship, type of AlloHCT, presence of GVHD, du-
ration of post-transplant remission, use of remission induction che-
motherapy prior to DCI and DCI cell dose.
Among pts treated with DCI, 36 (77%) hadmyeloidmalignancies.
Myeloablative regimen was used in 36 pts (77%) and 35 pts (74%)
had HLA-identical sibling donor transplant. 45 pts (96%) had grade
\2 aGVHD and 40 pts (85%) had limited or no cGVHD. Median
time of post-transplant relapse was 6.0 months (range, 0.9-84.6)
and the median time from transplant to DCI therapy was 7.8 months
(range, 2.3- 114). DCI was used once in 89% of pts and it was pre-
ceded with chemotherapy in 35 of 45 pts (78%). Median CD34
and TNC doses for the first DCI were 2.0x106 and 3.9x108 respec-
tively. The rate of post-DCI grade 3-4 aGVHD was 2% vs. 17%
for extensive cGVHD. With a median follow-up of 40.8 months
(range, 2.3-174.1), 38 pts (77%) had died and 29 (62%) relapsed. Re-
lapse was the most common cause of death (n5 25, 69%) after DCI.
Although pts who received unrelated DCI tended to have less post-
DCI relapses (42% vs. 69%), deaths (50% vs. 86%) or fatal events
due to relapse (50% vs. 73%), the numbers were too small to detect
statistically significant differences between groups. Recursive parti-
tioning analysis indicated that pts who had disease relapse within
20 months after transplant (n 5 39) were at higher risk of post-
DCI relapse, worse OS and RFS. Multivariable analysis demon-
strated that a bone marrow cell source was associated with poor
OS (HR 5 2.6; 95% CI 1.3-5.6, p 5 0.01) compared to peripheral
blood, and that post-transplant disease relapse within 20 months
was an adverse predictor for post-DCI relapse (HR 5 5.2; 95% CI
1.2-22.3, p 5 0.025), OS (HR 5 5.5; 95% CI 1.6-18.5, p 5 0.006)
and RFS (HR 5 3.5; 95% CI 1.2-9.9, p 5 0.02).
With long follow-up we demonstrated that disease relapse within
20months of AlloHCTportends poor clinical outcome despiteDCI,
but for patients with longer remission duration, DCI can result in
long-term progression free survival.
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN ADULT ALL PA-
TIENTS IN CR1: RESULTS OF UNRELATED DONORS ARE COMPARABLE
TO SIBLING DONORS?
Arnold, R.1, Terwey, T.1, Hemmati, P.1, le Coutre, P.1,
Schoenemann, C.2, Doerken, B.1, Massenkeil, G.2 1Charite University
Medicine, Berlin, Germany; 2Charite University Medicine, Berlin,
Germany
In the German Multicenter ALL Studies, patients (pts) with Ph+
ALL (very high risk, VHR), with high risk ALL (HR), e.g. B lineage
